<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519025</url>
  </required_header>
  <id_info>
    <org_study_id>PRO07080006</org_study_id>
    <secondary_id>investigator funding</secondary_id>
    <nct_id>NCT00519025</nct_id>
  </id_info>
  <brief_title>Risk Factors for Linezolid Resistance in Staphylococcus Aureus</brief_title>
  <official_title>Risk Factors for Linezolid Resistance in Staphylococcus Aureus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective chart review study. The proposed study aims to document the risk
      factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally,
      the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be
      assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective chart review study. The proposed study aims to document the risk
      factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally,
      the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be
      assessed. This research is important because identification of risk factors may allow earlier
      initiation of appropriate therapy in patients infected with these bacteria. Additionally, we
      will identify whether horizontal spread is responsible for this increasing trend.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Linezolid Resistance</condition>
  <condition>Staphylococcus Aureus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        linezolid resistance to staph aureus
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with linezolid resistance to staphylococcus aureus

        Exclusion Criteria:

          -  those that don't meet entry criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Potoski, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2007</study_first_submitted>
  <study_first_submitted_qc>August 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2007</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Brian Potoski</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Linezolid</keyword>
  <keyword>Staphylococcus Aureus</keyword>
  <keyword>Infections</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

